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Abstract
Background
Adjuvant chemotherapy in early stage breast cancer has been shown to reduce mortality in
a large meta-analysis of over 100 randomised trials. However, these trials largely excluded
patients aged 70 years and over or with higher levels of comorbidity. There is therefore
uncertainty about whether the effectiveness of adjuvant chemotherapy generalises to these
groups, hindering patient and clinician decision-making. This study utilises administrative
healthcare data—real world data (RWD)—and econometric methods for causal analysis to
estimate treatment effectiveness in these trial-underrepresented groups.
Methods and findings
Women with early breast cancer aged 70 years and over and those under 70 years with a
high level of comorbidity were identified and their records extracted from Scottish Cancer
Registry (2001–2015) data linked to other routine health records. A high level of comorbidity
was defined as scoring 1 or more on the Charlson comorbidity index, being in the top decile
of inpatient stays, and/or having 5 or more visits to specific outpatient clinics, all within the 5
years preceding breast cancer diagnosis. Propensity score matching (PSM) and instrumen-
tal variable (IV) analysis, previously identified as feasible and valid in this setting, were used
in conjunction with Cox regression to estimate hazard ratios for death from breast cancer
and death from all causes. The analysis adjusts for age, clinical prognostic factors, and
socioeconomic deprivation; the IV method may also adjust for unmeasured confounding fac-
tors. Cohorts of 9,653 and 7,965 were identified for women aged 70 years and over and
those with high comorbidity, respectively. In the�70/high comorbidity cohorts, median fol-
low-up was 5.17/6.53 years and there were 1,935/740 deaths from breast cancer. For
women aged 70 years and over, the PSM-estimated HR was 0.73 (95% CI 0.64–0.95),
while for women with high comorbidity it was 0.67 (95% CI 0.51–0.86). This translates to a
mean predicted benefit in terms of overall survival at 10 years of approximately3%
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Conclusions
The results of this study, as RWD, should be interpreted with caution and in the context of
existing and emerging randomised data. The relative effectiveness of adjuvant chemother-
apy in reducing mortality in patients with early stage breast cancer appears to be generalisa-
ble to the selected trial-underrepresented groups.
Author summary
Why was this study done?
• Women aged 70 years and over and with other health conditions were largely excluded
from participating in the clinical trials that established the efficacy of adjuvant chemo-
therapy in early breast cancer.
• An attempted trial for women aged 70 years and over was abandoned due to failure to
recruit participants, and observational data are therefore the best available option to
investigate the generalisability of chemotherapy effectiveness to trial-underrepresented
groups.
What did the researchers do and find?
• A retrospective cohort study was conducted using a population-based cancer registry
with linkage to other routinely collected health data in Scotland.
• Propensity score matching and instrumental variable methods were used to estimate the
effect of chemotherapy on breast cancer mortality and all-cause mortality, adjusting for dif-
ferences in prognosis between those who received chemotherapy and those who did not.
• The average predicted benefit of chemotherapy was an additional 3 out of every 100
women surviving for 10 years for those aged 70 years and over, and an additional 4 out
of every 100 for those with other health conditions.
What do these findings mean?
• These results support the generalisability of treatment effectiveness estimates for adju-
vant chemotherapy for early breast cancer to women aged 70 years and over and those
with other health conditions.
• These results should be interpreted with appropriate caution as they are estimated from
observational data and may be biased by residual confounding.
Chemotherapy in early breast cancer trial-underrepresented groups
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Introduction
The use of adjuvant chemotherapy after surgical treatment of early breast cancer is a major
contributor to the reduction in mortality from breast cancer over the last 3 decades. A global
collaboration of trialists published a definitive individual patient data meta-analysis of more
than 100,000 women with breast cancer, concluding that chemotherapy reduces the risk of
dying from breast cancer by about a third [1,2]. However, the clinical trials upon which this
evidence relies were performed in highly selected patient populations including few patients
older than 70 years or patients with other significant health conditions. In routine clinical
practice there are many patients who would never have been included in those trials due to
advanced age, comorbidity, or frailty. The decision of whether or not to administer or undergo
adjuvant chemotherapy is informed solely by evidence from the ‘trial eligible’ patient popula-
tion. Therefore, decisions are based on the assumption that the estimated treatment effect is
generalisable, despite differences in personal characteristics.
A lack of evidence of generalisability of clinical trial results (the problem of external valid-
ity) has been recognised as a major barrier to translating research findings into changes in clin-
ical practice [3]. Generalisability of experimental findings to the populations seen in clinical
practice can be maximised by designing trials to be pragmatic, having wide inclusion criteria
for patients, recruiting patients into trials from a variety of typical clinical settings, reducing
differences between trial protocols and clinical practice, and obtaining data on relevant out-
comes or adverse events [4].
Attempts to address a perceived lack of generalisability in the evidence base for adjuvant che-
motherapy in patients aged 70 years and over by conducting further randomised controlled trials
have failed due to poor recruitment [5,6]. In the pilot phase of the ACTION trial, a lack of equi-
poise on the part of both clinicians and patients was noted as the major reason for an unwilling-
ness to participate in randomisation. The persistent lack of direct trial evidence for women aged
70 years and over engenders considerable uncertainty about the balance of patient benefit and
harm from chemotherapy, which may lead to suboptimal treatment decisions and unwarranted
variation in practice. When randomised studies are infeasible, as may be the case here, alterna-
tive methods using observational data may represent the best available source of evidence on
treatment effectiveness. Observational data from routine sources have the potential to enhance
external validity but at a cost of additional potential bias arising from the research design [7]. A
lack of randomisation means that unaccounted for differences between patients who receive
treatment and those who do not may bias results, a feature called residual confounding.
Prior analysis of Scottish Cancer Registry data demonstrated that several real world evi-
dence (RWE) methods utilising available routine data from otherwise healthy women under
70 years are feasible and may give comparable results to randomised data in estimating the
effectiveness of chemotherapy in early stage breast cancer [8]. Hazard ratios for breast cancer
mortality in the trial-represented population were concordant between RWE and a rando-
mised trial meta-analysis. However, results for all-cause mortality were less concordant, indi-
cating a greater potential for bias in relation to this outcome [8].
This study aims to estimate the effectiveness of adjuvant chemotherapy for early stage breast
cancer in reducing mortality for women aged 70 years and over and for women with a high
level of comorbidity using real world data (RWD). The estimates are presented for consider-
ation alongside available evidence from the trial-represented population.
Methods
A retrospective cohort study design was used. All records of women with primary invasive
breast cancer (ICD-10 C50) diagnosed from 1 January 2001 to 31 December 2015 were
Chemotherapy in early breast cancer trial-underrepresented groups
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retrieved from the Scottish Cancer Registry. Linkage to routine outpatient and inpatient rec-
ords (ISD Scotland datasets SMR00 and SMR01, 1996 to 2017) was achieved using each
patient’s uniquely identifying Community Health Index (CHI) number. Selection and linkage
was provided by ISD Scotland. Use of these anonymous data in this research project was
reviewed and approved by the NHS Scotland Public Benefit and Privacy Panel. Follow-up of
vital status was available to April 2017. Women with first breast cancer were identified based
on the first chronological record of diagnosis code ICD-10 C50 for the unique patient identi-
fier. In the case of multiple simultaneous records, the record with the most complete data was
selected. If completeness was identical then the record with the worse prognosis (PREDICT
score) was selected. When records were identical in all extracted variables, the duplicate rec-
ords were deleted.
Exclusion criteria included male sex, advanced cancer (clinical M stage = 1), no recorded
surgery, or recorded neoadjuvant therapy (chemotherapy or hormone therapy prior to sur-
gery). PREDICT (version 2) prognostic scores [9] were estimated for all patients with complete
input data. The prognostic algorithm has previously been shown to be well calibrated in this
population [10]. Further details of the dataset and variables are available in [8].
The�70 patient group was selected based on age at date of diagnosis being 70 years or
greater. Based on clinical expert opinion, high comorbidity was defined as meeting 1 or more
of 3 conditions: (1) a score of 1 or more on the Charlson comorbidity index [11] based on
inpatient records from the previous 5 years, (2) total inpatient bed days in the previous 5 years
in the top decile (6 or more) of the full cohort, and/or (3) 5 or more outpatient visits to respira-
tory, cardiology, or rheumatology specialties in the previous 5 years. Women aged 70 years
and over were excluded from the high comorbidity group. A sensitivity analysis selected
women aged 70 years and over excluding those with high comorbidity.
Statistical analysis
The choice of statistical analysis was determined based on prior assessment of the feasibility
and validity of a range of econometric methods in the trial-represented population of cases
from the same registry [8]. The study proposal for data analysis is included in S1 Text. The
plan originally included only the regression discontinuity design but was later expanded to
include regression adjustment, propensity score matching (PSM), and instrumental variable
(IV) designs.
Two RWE designs—PSM and IV—were used to obtain estimates of adjuvant chemotherapy
effectiveness. PSM was conducted using a propensity score as constructed in [8] with 1:1 near-
est-neighbour matching within callipers, without replacement. Propensity scores were esti-
mated using probit regression with the following explanatory variables: PREDICT 10-year
probability of mortality, age at diagnosis, number of positive lymph nodes, pathological
tumour size, tumour histological grade, mode of detection, estrogen receptor (ER) status,
HER2 status, hormone therapy use, radiotherapy use, year of diagnosis, Scottish Index of Mul-
tiple Deprivation (SIMD) quintile, Charlson comorbidity index, log total inpatient bed days
(in the 5 years prior to diagnosis), and log total outpatient visits (in the 5 years prior to diagno-
sis). Interactions of other clinical prognostic factors with ER status were also included. Two
versions of the IV approach were estimated using (1) PREDICT chemotherapy benefit score
and (2) PREDICT chemotherapy benefit score interacted with a post-2010 dummy variable.
Two-stage residual inclusion was used to implement the IV approach as this is suitable when
both the treatment and the outcomes are limited dependent variables [12]. Confidence inter-
vals were calculated by simple bootstrap with 1,000 replications. Full details and justification
for the selection of these RWE designs and specifications as the most suitable means of
Chemotherapy in early breast cancer trial-underrepresented groups
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providing estimates of adjuvant chemotherapy are available in [8] and S2 Text. The analyses
were repeated for the outcomes of breast cancer mortality and all-cause mortality. Breast can-
cer mortality was defined as a breast cancer code recorded as the primary cause of death or 1
of the 3 contributing causes of death in the death certificate.
Directly comparable estimates of adjuvant chemotherapy effectiveness are taken from the
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis. The EBCTCG
meta-analysis estimated that the HR for mortality from breast cancer for newer anthracycline
regimens versus placebo was 0.71 (95% CI 0.62 to 0.83) [2]. The corresponding HR for all-
cause mortality was 0.83 (95% CI 0.73 to 0.94).
HRs were estimated for comparison with trial meta-analysis reports, but HR is very limited
for informing clinical decisions. Therefore, we have applied the estimated HR in a recalibrated
version of the PREDICT model to produce an estimate of survival benefits (absolute risk
reductions) over 10 years for all women in the sample for each group. This analysis was added
following reviewer comments to aid clinical interpretation. Recalibration replaced the coeffi-
cient for chemotherapy use with a coefficient corresponding to the PSM-estimated HR for
each group in this study. Expected benefit estimates were stratified in 5-year age bands for
women aged 70 years and over, while women with comorbidities were stratified into 3 groups
in 10-year age bands from 40 to 69 years. For the high comorbidity group, an additional hazard
of non-breast-cancer death (HR ranging from 1–5) was applied to reflect how additional mor-
tality from specific comorbidities might impact chemotherapy benefits (a method similar to
that previously used in the [now defunct] Adjuvant Online! decision tool, in which the clini-
cian could specify an additional risk of mortality [13]). Mean benefit from chemotherapy and
the proportion of women with benefit at or above the guideline thresholds of 3% and 5% [14]
were calculated.
Results
A total of 9,653 and 7,965 eligible patient records were identified for the�70 group and the
high comorbidity group, respectively (Fig 1). Patient characteristics in the�70 and high
comorbidity groups are displayed in Table 1.
The results of PSM sample balance tests and IV first-stage results are available in S2 and S3
Tables. Good balance was demonstrated for both of the matched samples, with no clinically
important differences in important covariates between treated and untreated groups. First-
stage results for the IV analysis indicated statistically significant effects of the proposed instru-
ments on the probability of receiving the treatment (�70 IV1: 0.49 [95% CI 0.37–0.6],
P< 0.001; IV2: 0.14 [95% CI 0.04–0.23], P = 0.006; high comorbidity IV1: 0.41 [95% CI 0.26–
0.56], P< 0.001; IV2: 0.1 [95% CI 0.02–0.18], P = 0.012), an important assumption of the
method. The estimated hazard ratios for death in women aged 70 years and over and women
with high comorbidity are displayed in Table 2.
Breast cancer mortality hazard ratios for women aged 70 years and over and those with
high comorbidity are consistent with trial meta-analysis estimates. There was a closer match
with the PSM estimates and somewhat lower HRs reported using the IV method. The confi-
dence intervals indicate that sufficient uncertainty remains such that identical HRs between
any of these methods and the trial meta-analysis cannot be ruled out at conventional thresh-
olds, i.e., there was no strong evidence against generalisability. Overall results indicate a benefi-
cial effect for chemotherapy at conventional statistical thresholds with the exception of IV1 for
breast cancer death and IV1 and IV2 for all deaths in the high comorbidity group. Results
were not sensitive to excluding women with high comorbidity from the�70 group (S4–S6
Tables).
Chemotherapy in early breast cancer trial-underrepresented groups
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Tables 3 and 4 translate these results into clinically meaningful estimates of overall survival
benefit using a recalibrated version of the PREDICT model. For women aged aged 70 years
and over, predicted benefits over 10 years average around a 3-percentage-point increase in sur-
vival. Benefits of 3% and above were estimated for approximately 40% of women of any age,
while benefits of 5% and above were estimated for approximately 20% of women up to the age
of 85 years. Over the age of 85 years, there are few women with predicted benefits at or above
the 3% threshold and almost none at or above the 5% threshold. The actual proportion of
women aged 70 years and over who received chemotherapy was 10.2%.
In younger age groups with high comorbidity, the benefits are commensurably greater due
to less age-related competing risk of mortality from non-breast-cancer causes. Predicted sur-
vival benefit from chemotherapy is related to the assumed increased hazard of mortality from
other causes, but only weakly. Even with a relatively large additional risk of mortality from
comorbidity (HR = 5), the mean absolute benefit and proportion of women at or above the 3%
Fig 1. Patient record selection.
https://doi.org/10.1371/journal.pmed.1003006.g001
Chemotherapy in early breast cancer trial-underrepresented groups
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and 5% thresholds are largely preserved. The actual proportion of women under 70 years with
high comorbidity who received chemotherapy was 32.1%.
Discussion
These observational data suggest that the relative effectiveness of adjuvant chemotherapy in
reducing mortality in women with early stage breast cancer appears similar for trial-underrep-
resented groups (aged 70 years and over and high comorbidity) and trial-eligible groups. If
one accepts that the additional assumptions required by RWE methods are met in this case,
then this would imply that estimates of treatment effectiveness among trial-eligible patients are
generalisable to these trial-underrepresented groups. These results are also in agreement with
previous studies using observational data from the Surveillance, Epidemiology, and End
Results (SEER) database for women aged 65 years and above [15].
Limitations
The main limitation relating to this analysis is that, despite use of the more robust RWE meth-
ods for causal inference, there remains potential for bias in these results from residual con-
founding [7]. Residual confounding may arise from lack of data regarding chemotherapy
regimens, limited use of the full dimensionality of the comorbidity data, or from as yet
unknown confounding variables. For this reason, these results are not a direct substitute for
evidence from a high-quality randomised trial. Data included in this study are from a single
country, which may limit generalisability to other settings.
Strengths
A strength of this study is the use of a large population-based cohort of patients with high-
quality outcome determination and covariate information obtained from data linkage. Previ-
ous studies using SEER data did not have access to the same range of covariates. To our knowl-
edge, no previous study has tested the feasibility of alternative methods of analysis to the same
extent as was undertaken in this research. Use of a population-based cohort enhances external
validity, allowing better assessment of effectiveness in clinical practice as opposed to efficacy in
a highly selected trial population.
Table 1. Summary statistics of trial-underrepresented group samples from the Scottish Cancer Registry, 2001–
2015.
Characteristic �70 years High comorbidity
Total number of patients 9,653 7,965
Total time at risk (years) 56,864 57,094
Median follow-up (years) 5.17 6.53
Number of breast cancer deaths 1,935 740
Number of other deaths 2,018 648
Five-year survival rate 74.7% 87.2%
Median age at diagnosis, years 76 60
Age 76.65 (0.05) 58.75 (0.14)
Tumour size (mm) 24.68 (0.16) 19.79 (0.21)
Inpatient days (in the 5 years prior) 4.99 (0.15) 13.39 (0.45)
PREDICT benefit score 3.02 (0.02) 2.68 (0.04)
Outpatient visits (in the 5 years prior) 7.22 (0.10) 12.68 (0.25)
Data given as mean (SD) unless otherwise indicated. Additional summary statistics available in S1 Table.
https://doi.org/10.1371/journal.pmed.1003006.t001
Chemotherapy in early breast cancer trial-underrepresented groups
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How this study can inform future research
An important issue that this study informs is whether or not additional randomised trials are
needed in the trial-underrepresented groups we have identified. Our results suggest that trials
conducted within these groups with a no-chemotherapy arm are probably neither necessary
nor desirable. A beneficial treatment effect, consistent with the reported trial meta-analysis,
was observed in both groups. While previous attempts to conduct trials in women aged 70
years and over proved infeasible due to lack of recruitment, our results may change the clinical
community’s interpretation of the existing evidence and willingness to recruit such women to
trials comparing 2 forms of therapy, although patients’ perception of the risks and benefits and
willingness to participate may remain a barrier. Also, some additional randomised data may
become available in more selected populations. Randomisation is being conducted among
patients classified into specific risk groups in ongoing studies [16,17], and standard adjuvant
chemotherapy is a control arm in trials of new targeted therapies [18,19]. These trials will pro-
vide some new randomised data in the�70 age group, as the age restrictions are more relaxed
in most of these trials than was the case in previous studies. However, the total number of
patients randomised in this group may still be small.
Table 2. Hazard ratios for death from breast cancer and all causes in women aged 70 years and over and women with high comorbidity.
Real world evidence method N Breast cancer death Death from any cause
Deaths HR 95% CI Deaths HR 95% CI
Reference1 0.71 0.62–0.83 0.83 0.73–0.94
Women aged�70 years
PSM 1,298 431 0.78 0.64–0.95 568 0.71 0.60–0.85
IV1 9,653 1,935 0.57 0.42–0.74 3,953 0.61 0.49–0.74
IV2 9,653 1,935 0.57 0.42–0.73 3,953 0.63 0.50–0.76
Women with high comorbidity
PSM 2,034 254 0.67 0.51–0.86 421 0.67 0.56–0.82
IV1 7,965 740 0.68 0.42–1.10 1,388 0.92 0.63–1.33
IV2 7,965 740 0.59 0.37–0.99 1,388 0.82 0.58–1.22
1Early Breast Cancer Trialists’ Collaborative Group meta-analysis of newer anthracycline-containing regimens versus placebo [2].
IV, instrumental variable; PSM, propensity score matching.
https://doi.org/10.1371/journal.pmed.1003006.t002
Table 3. Predicted survival benefit with chemotherapy for women aged 70 years and over.
Age N Predicted 10-year
survival without chemo
(%)
Predicted 10-year
survival with chemo
(%)
Mean absolute
mortality benefit
(%)�
Proportion with
�3% benefit (%)
Proportion with
�5% benefit (%)
Observed actual percent
that received adjuvant
chemo
70–
74
3,955 57.9 62.x 2.9 39.6 19.2 18.2
75–
79
3,131 45.8 49.6 3.1 44.2 18.9 7.3
80–
84
1,784 32.x 35.4 3.x 46.4 17.3 1.5
85–
99
681 17.3 20.4 3.x 48.8 9.7 0.6
90–
95
95 6.x 8.6 2.7 43.2 0 0
�Percentage point improvement in survival at 10 years.
chemo, chemotherapy.
https://doi.org/10.1371/journal.pmed.1003006.t003
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A recommendation for future research is that the RWE estimates produced here should be
replicated using comparable routinely collected data from other regions or countries. This is
an important step in validating the results and could help to identify any biases arising from
measurement or selection in these specific routine datasets. As RWD are not gathered solely
for the purposes of research, the measurement and recording of some variables may be subop-
timal in any given RWD [20]. One advantage of RWD is that replication is relatively inexpen-
sive and does not raise additional ethical concerns related to equipoise, in contrast to
replication of a randomised trial. Following replication of our results, a careful synthesis of
both observational and trial data results should be attempted. This must reflect all the available
data as well as current beliefs about treatment effect generalisability in this context. An impor-
tant future direction for RWE will be to undertake more specific exploratory analysis to look
for predictors of outcome within trial-underrepresented groups. This type of analysis will be
useful to inform targeted data collection within specific underserved or at-risk groups.
How this study can inform clinical practice
This analysis can inform treatment guidelines and patient information in trial-underrepre-
sented groups—as exemplified in our presentation of expected benefits in terms of absolute sur-
vival using a recalibrated decision tool. Additional methodological development is also needed
to support this type of evidence synthesis. First, more clarity is needed around the best methods
for synthesis of observational and randomised data [21]. Second, methods must also address the
generalisability of effectiveness estimates beyond the trial population, based on both extrapola-
tion from existing data and prior beliefs based on other knowledge of the topic of study.
Evidence from observational data using RWE methods supports the generalisability of
treatment effectiveness estimates for adjuvant chemotherapy for early breast cancer to women
aged 70 years and over and those with high levels of comorbidity. The results of this study, as
with all RWE, should be interpreted with appropriate caution and in the context of existing
and emerging randomised data.
Table 4. Predicted survival benefit with chemotherapy for women aged under 70 years with high comorbidity.
Age and additional
hazard of non-BC
death
N Predicted 10-year
survival without
chemo (%)
Predicted 10-year
survival with chemo
(%)
Mean absolute
mortality benefit
Proportion with
�3% benefit (%)
Proportion with
�5% benefit (%)
Observed actual percent
that received adjuvant
chemo
Age 40–49 years 673 62.2
1 73.4 81.3 5.1 61.7 41.5
1.5 72.3 80.1 5.1 61.4 41.2
2.5 70.1 77.7 5.x 60.3 40.3
5 64.9 72.2 4.7 59.7 38.6
Age 50–59 years 2,991 36.3
1 79.4 84.1 3.4 37.4 24.5
1.5 77.1 81.7 3.3 37.1 23.9
2.5 72.7 77.1 3.2 36.6 23.2
5 62.8 67.x 3.1 35.8 21.3
Age 60–69 years 3,793 23.1
1 73.2 77.2 3.3 36.4 22.5
1.5 68.4 72.3 3.2 35.7 21.9
2.5 59.8 63.5 3.x 35.1 20.6
5 42.9 46.3 2.9 34.2 18.8
BC, breast cancer; chemo, chemotherapy.
https://doi.org/10.1371/journal.pmed.1003006.t004
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